CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Biological: COVID-19 convalescent plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug926 artus Influenza A/B RT-PCR Test Wiki 1.00

Correlated MeSH Terms (9)

Name (Synonyms) Correlation
D003384 Coxsackievirus Infections NIH 1.00
D000257 Adenoviridae Infections NIH 0.71
D018184 Paramyxoviridae Infections NIH 0.58
D018357 Respiratory Syncytial Virus Infections NIH 0.50
D007251 Influenza, Human NIH 0.38
D003141 Communicable Diseases NIH 0.12
D014777 Virus Diseases NIH 0.11
D007239 Infection NIH 0.08
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

I. Study Design: This is a single-arm feasibility study to assess the safety and efficacy of anti-SARS-CoV-2 convalescent plasma (CP) in 1. intubated, mechanically ventilated patients with confirmed COVID-19 pneumonia by chest X-ray or chest CT. 2. hospitalized patients with acute respiratory symptoms between 3 and 7 days after the onset of symptoms, with COVID-19. II. Study Population: 1. Population 1: Mechanically ventilated intubated COVID-19 patients aged 18 years or older. 2. Population 2: Hospitalized COVID-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7 days from the beginning of illness. III. Study Agent: SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL at neutralization antibody titer >1:160.

NCT04358211 COVID-19 Biological: Biological: COVID-19 convalescent plasma


No related HPO nodes (Using clinical trials)